AllJournalThesisConferenceNewspaperPatentStandardYear BookBook|ResearcherProject
all languages  Chinese Only  Other Languages
Author:... Oriana López-Godino , Eulogio Conde , Dolores Caballero
Data Source:[J].Biology of Blood and Marrow Transplantation(IF 3.94), 2017, Vol.23 (1), pp.53-59Elsevier
Abstract:Abstract(#br)We designed a phase II clinical trial including Y-90 ibritumomab-tiuxetan as part of a reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (Clinical Trials Identifier: NCT00644371). Eligible patie...
Author:Dolores Caballero , Lucrecia Yáñez ...
Data Source:[J].Biology of Blood and Marrow Transplantation(IF 3.94), 2017Elsevier
Abstract:Abstract(#br)High-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) has contributed to modify the natural history of follicular lymphoma (FL); however, an overall survival (OS) benefit has been demonstrated at relapse only after a rituximab-free ...
Author:Dolores Caballero , Molly Maloy ...
Data Source:[J].Biology of Blood and Marrow Transplantation(IF 3.94), 2018, Vol.24 (5), pp.964-972Elsevier
Abstract:Abstract(#br)Reduced-intensity conditioning (RIC) and T cell depletion (TCD) through CD34 + cell selection without the use of post-transplantation immunosuppression are 2 strategies used to reduce nonrelapse mortality (NRM) in older patients after allogeneic hematopoietic ce...
Author:Dolores Caballero , Per Ljungman ...
Data Source:[J].Medical Oncology(IF 2.147), 2018, Vol.35 (6), pp.1-8Springer
Abstract:Abstract(#br)Chronic graft-versus-host disease (cGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Aim is to identify risk factors for the development of cGVHD in a multicenter setting. Patients transplanted be...
Author:Dolores Caballero , Claire Dearden ...
Data Source:[J].Cancer Treatment Reviews(IF 6.024), 2014, Vol.40 (9), pp.1080-1088Elsevier
Abstract:Abstract(#br)Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lymphomas with a very poor prognosis. Current therapies, based on historical regimens for aggressive B-cell lymphomas, have resulted in insufficient patient outcome...
Author:Dolores Caballero , María-Consuelo del Cañizo
Data Source:[J].Biology of Blood and Marrow Transplantation(IF 3.94), 2014, Vol.20 (10), pp.1580-1585Elsevier
Abstract:Abstract(#br)We evaluated the feasibility, safety, and efficacy of the administration of 4 sequential doses (intravenously administered on days 1, 4, 11, and 18) of cryopreserved bone marrow–derived mesenchymal stromal cells (MSC) expanded with platelet lysate and obtained f...
Author:Dolores Caballero , Carmen Martinez ...
Data Source:[J].Biology of Blood and Marrow Transplantation(IF 3.94), 2016, Vol.22 (3), pp.584-588Elsevier
Abstract:Abstract(#br)Allogeneic stem cell transplantation (allo-HCT) represents the most effective immunotherapy for acute myeloid leukemia (AML) and myeloid malignancies. However, disease relapse remains the most common cause of treatment failure. By performing a second allo-HCT, d...
Author:Dolores Caballero , Cristina Joao ...
Data Source:[J].The Lancet(IF 39.06), 2016, Vol.387 (10020), pp.770-778Elsevier
Abstract:Summary(#br)Background(#br)Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the e...

Being retrieved, please wait for a moment...

International Cooperation:cnki.scholar@cnki.net, +86-10-82896619   Feedback:scholar@cnki.net

×